## conferenceseries.com

## **7<sup>th</sup> Obesity & Endocrinology Specialists Congress**

October 10-12, 2016 Manchester, UK

			• 4	•	oo.	4	e
А	SV	ner	gist	7C (	etta	PCT	ΛŤ
7 B	O 1					···	V.

extracts and alginate on inhibition of lipase

Moaz Zulali, Chris Ward and Jeffrey Pearson New Castle University, UK

Desity is one of the most important issues in global health. Or listat is the only approved pharmaceutical treatment for obesity. However, side e ects may appear in individuals who use Or listat such as fecal incontinence, oily spotting, and increased defecation frequency. Other lipase inhibitors derived from natural products such as seaweed are being investigated. However, their side e ects on lower bowel function are likely to be similar to Or listat. In order to reduce GI side e ects, we are investigating synergistic e ects of brous alginate and seaweed extracts. ree types of alginate were added to 3 di erent f. e ic extracts, and the ability of the mixtures to inhibit lipase activity was tested. A modi cation of the method of was used to determine the inhibitory e ects of the mixtures of f. e ic extracts and alginates on lipase activity. is study showed that all f c e ic extracts tested can inhibit lipase activity. All the extracts had a similar inhibitory e ects1hibiA indc.a,tat/t(d f)-9.9 (r)1s-2.9 (a)9e9 (u)0.9 (lo)2P]TJ0.019 TDMB (a)

**Notes:**